Table 1.

Baseline characteristics and serologic response to BNT162b2 vaccine in patients with immune-mediated kidney disease receiving rituximab

Patient	Age (years)	Gender	Kidney disease	Disease duration before vaccine (months)	Last RTX dose (mg)	Time between last RTX dose and vaccine (months)	eGFR (mL/min/1.73 m²)	UPCR (g/g)	sAlb (g/L)	IgG (g/L)	CD19⁺ lymphocyte count before vaccination (µL⁻¹)	Anti-RBD Ab level (U/mL)^a before and 28 days after second vaccine dose
Patient	Age (years)	Gender	Kidney disease	Disease duration before vaccine (months)	Last RTX dose (mg)	Time between last RTX dose and vaccine (months)	eGFR (mL/min/1.73 m²)	UPCR (g/g)	sAlb (g/L)	IgG (g/L)	CD19⁺ lymphocyte count before vaccination (µL⁻¹)	Before	After
1	36	M	AAV-PR3	77	500	1.9	46	0.2	46	10.5	0	4.7	>250.0
2	72	F	AAV-PR3	205	1000	6.8	47	0.3	40	8.5	0	1.9	2.2
3	46	F	MCD/FSGS	42	1000	3.4	59	1.0	39	4.1	0	<0.8	5.5
4	19	M	MCD/FSGS	177	1000	7.8	123	0.2	50	10.7	103	<0.8	>250.0
5	37	M	MN	108	1000	2.4	81	0.5	45	13.8	121	<0.8	>250.0
6	37	M	AAV-PR3	12	1000	4.9	67	2.0	40	7.4	0	<0.8	<0.8
7	36	F	AAV-PR3	42	1000	2.1	74	0.1	46	11.8	0	<0.8	<0.8
8	68	M	AAV-PR3	51	750	1.8	90	0.2	44	5.8	0	<0.8	<0.8
9	38	F	AAV-MPO	37	500	3.5	97	0.1	47	10.0	0	<0.8	<0.8
10	57	F	AAV-MPO	56	500	2.4	62	0.2	42	12.2	80	<0.8	<0.8
11	61	M	MCD/FSGS	118	500	0.7	46	0.4	43	7.8	0	<0.8	<0.8

RTX, rituximab; eGFR, estimated glomerular filtration rate determined by the Chronic Kidney Disease Epidemiology Collaboration equation; UPCR, urinary protein:creatinine ratio; sAlb, serum albumin; IgG, serum immunoglobulin G; Ab, antibodies; M, male; F, female; AAV, ANCA-associated vasculitis; MCD/FSGS, minimal change disease/focal and segmental glomerulosclerosis; MN, membranous nephropathy. ^aPositivity cut-off: 0.8 U/mL.